Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

BICO, Audiocast, Q1'26

By Inderes4/29/2026, 8:00 AM
BICO Group

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Maria Forss
00:01 - 08:14

Hello and welcome to BICO Group AB's Quarter One, 2026 Earnings Call. I'm Maria Forss president and CEO, and I will, together with BICO AB CFO Ewa Linsäter, present this interim report. Here is today's agenda. I will open today's session by summarizing quarter one, 2026 and also describe how BICO serves the world's leading pharma and biotech companies with solutions that transform how labs operate, innovate, and solve our customers' challenges. Following that, Ewa will present the group's financial performance. I will then comment on our R&D pipeline with our ongoing product development efforts. Additionally, I will highlight some recent and upcoming product launches. The session will conclude by highlighting our focus for 2026 before we open up for Q&A. A strong start to the year with 11% organic growth, navigating a dynamic market still affected by geopolitical uncertainty, weak academic funding in the US, and continued currency headwinds. Our total reported growth was -1.4%. All numbers presented are in million Swedish kronor unless otherwise stated. EBITDA was -42 million with adjusted EBITDA of -11 million. And the difference is mainly related to a restructuring cost of 52 million, of which 30 million affected EBITDA. Cash flow from operating activities totaled 47 million and we successfully issued senior secured bonds of €40 million. And the new capital puts us in a position to support further growth and capture a market recovery while navigating ongoing macroeconomic uncertainty. A property in Åland, Finland carved out from the divestment of Denali, was also divested for a total of €3.5 million. We settled all our convertible bonds originally issued in 2021, with a total outstanding amount of 1,008,000,000 Swedish kronor in full on their scheduled maturity date. Before Ewa provides more details on our financial performance, I will present how BICO serves the world's leading pharma and biotech companies with solutions transforming how labs operate and innovate, which is what our vision is about. Our customers all share one ambition: reducing time to market and increasing the probability of success. With our leading software suite, Green Button Go, together with off-the-shelf automation products as well as bioprinting, our portfolio is in the sweet spot of meeting that ambition and solving their core challenges with long and costly development cycles. Our solutions enable smarter, faster and more efficient labs. Here lies an underlying strong demand. Pharma biotech companies all face the same fundamental challenge: long, costly development cycles for new therapies. The development of a new therapy often takes more than ten years and costs between 2 and 4 billion USD, with the probability of approval after Phase 1 at just 10%. To overcome this, our pharma and biotech customers are investing heavily in automation and AI to increase efficiency, speed and quality, to bring innovations to market faster and at a lower cost. Our products and services enable our customers to connect data across systems and apply AI tools to plan, run and optimize experiments in real time. We are enabling AI-driven drug discovery workflows through our Green Button Go platform, connecting workflows and data streams. The AI acceleration shifts the bottleneck to the wet lab where our automation solutions are at the core, and I will explain how Green Button Go enables AI-powered automation in the wet lab to ease this bottleneck. AI accelerates discovery. And then the wet labs become the new bottleneck. Generative models and predictive biology dramatically speed up hypothesis generation. Yet, wet lab validation remains the hard constraint. In fact, more AI-driven candidates need more experiments, not fewer. Intensifying pressure on lab throughput, system uptime, and data reproducibility. This means that wet labs become more critical rather than obsolete. AI breakthroughs have made wet labs even more central to R&D. The lab is now a biological compute cluster, validating AI predictions. So high-throughput automation and trusted data become mission-critical. So all in all, BICO AB automation provides the trusted execution and validation layer that converts AI-generated hypotheses into proven experimental evidence. We have already integrated assistive AI into our platforms, bringing natural language workflow creation and troubleshooting in Green Button Go, making automation accessible to every scientist. And we are also developing next-generation systems like Crescendo to scale up experiments while keeping human-in-the-loop oversight. So by emphasizing reliability, data integrity, and compliance, we ensure the coming surge of AI-driven experiments can run at scale without compromising quality or uptime. This execution-focused strategy cements our platform as indispensable infrastructure in an AI-powered biotech landscape, making AI an opportunity for us rather than a threat. And this leads us to our vision, which has been updated this quarter because it has been developed to position us as more visionary and with a clear portfolio cohesion and direction in line with the BICO 2.0 strategy and portfolio. And from this quarter, we are reporting BICO as one operating unit, which reflects the integrated operating model, shared resources and joint strategic initiatives across the group. Our updated vision is to enable life science labs to accelerate the discoveries that change lives, with a mission where BICO leverages a global portfolio of pioneering brands fusing automation, intelligence and data to unlock scientific discovery at scale. Ultimately, we support customers to advance science so therapies can reach people faster. Customers using BICO AB automation solutions consistently report measurable gains in productivity and reliability, including reduced hands-on time, faster turnaround times, and higher instrument utilization. Let me show you one example that emphasizes the value BICO delivers to our customers. The data shown here are from one of the top pharma customers we are serving, and they kindly share their efficiency improvements by using our lab automation solutions. Downstream process and assay development was reduced by 75%, and the capacity with existing equipment they already had was boosted by 400%. Because parallel processing and variable-driven robotic processes allow for more uptime to be squeezed out of each piece of equipment in the lab. And ultimately, these productivity increases mean that their scientists are able to achieve 200% of their original productivity. And this is because the automation was coming alongside them, supporting them, taking over the manual steps and running concurrently in ways that a person just can't manage alone. And this is just one example of a lab leveraging Green Button Go. And we're taking technology and using it to augment the work of humans to get to innovation faster. So to summarize, we lead the way in solving the challenges in life science with speed, accuracy, and efficiency. All in all, our customers can run their processes faster, improve their quality of data, and ultimately make better decisions. I will now hand over to Ewa to present the results for the first quarter.

Ewa Linsäter
08:16 - 14:34

Thank you Maria. I will now provide more details on the numbers presented by Maria. After a strong start in January with a positive outlook, the market was again affected by geopolitical uncertainty with tariffs and war. The weak academic funding seen in 2025 has continued during Q1, where academic end markets remain soft with cautious spending and delayed capital equipment purchases. Despite this general trend, we see some pockets of sales improvement also in academia. For the Academia segment during the quarter, total organic growth was 11%, as of this quarter we are reporting BICO AB as one single operating segment following the divestment of three bioprinting companies, a step towards a more consolidated business. The portfolio is now more focused on lab automation and software intelligence across our entire business. And this reinforces the one BICO approach, where strategic decisions and performance evaluations are made on a consolidated basis. This reporting, which is now focused on the group as a whole, reflects the integrated operating model, shared resources and joint strategic initiatives across the group. Navigating these dynamic market conditions, sales in Q1 amounted to 330 million SEK, an organic growth of 11%, mainly deriving from strong desktop instrument sales. The 12 percentage points difference between reported and organic growth can be explained by FX headwinds, mainly due to the weaker US dollars against the Swedish krona. We have revised our reported sales categories into instruments, consumables and service. Other lab automation projects have previously been grouped as a single category and are now split into instruments for the product part and into service and other for the software and installation parts. In Q1, we saw growth in the instruments and consumables segments. EBITDA amounted to -42 million and adjusted EBITDA was -11 million. The difference mainly relates to one-off restructuring costs of 52 million, of which 30 million affected the EBITDA. These restructuring costs are connected to a program launch during the quarter. The aim is to improve cost efficiency, further simplify the operating model, and improve R&D pipeline execution in one of the business units. The program includes organizational streamlining as well as a planned closure of one site in Europe. We also have aligned some group functions to our current business needs. These programs will yield annualized savings of about 30 million. Even if we see a decline in the gross profit margin compared to the same quarter last year, mainly due to unfavorable product mix. The adjusted EBITDA improved as a result of increased sales as well as continued cost control activities. One example is legal costs, where we have invested in legal competencies in-house, which has led to reduced external legal costs in a growing, yet still emerging and increasingly demanding market. We continued during the quarter to address execution challenges in parts of our lab automation business, primarily related to complex projects. These initiatives are receiving focused management attention, and we are actively implementing targeted measures to strengthen execution, enhance scalability, and reinforce our competitiveness going forward. Cash flow from operating activities amounted to 47 million, positively impacted by working capital changes of 79 million during the quarter. We settled our convertible bond and also issued new Senior Secured Bonds. We sold our Finnish property with net proceeds of 32 million. The total cash flow during the first quarter amounted to -547 million. Due to the settlement of the convertible bonds of 1,008,000,000 SEK. Cash reserves by the end of the period were 744 million. As mentioned on the previous slide, the changes in working capital resulted in a positive effect of 79 million compared to the previous quarter. Operating receivables decreased by 146 million. Inventories increased by 13 million. Operating liabilities decreased by 55 million. Net working capital in relation to sales in the quarter corresponded to 7%. The low working capital is a consequence of reduced accounts receivable, as our sales normally are lower in the first half of the year, but also fewer new large projects started. Over time, we expect working capital in relation to sales to be in line with the industry standard of closer to 20% of sales. As previously mentioned, we issued senior secured bonds in January with a total nominal value of €40 million. The bonds have a tenure of four years and the carrying floating interest rate of three months euribor, plus a margin of 5.9%. As Maria has mentioned earlier, the new capital puts us in a position to support further growth and capture market recovery while navigating ongoing macroeconomic uncertainty. The transaction also serves as a clear testament to the capital markets continued confidence in BICO. I will now hand over to Maria to present the R&D portfolio and some recent product launches.

Maria Forss
14:35 - 19:27

Thank you Ewa. One focus area for growth is continuous product innovation, and we have a solid R&D pipeline and roadmap in place at BICO. And this is based on the portfolio strategy, which is part of BICO 2.0. On this slide, you can see our comprehensive product development pipeline within BICO AB's prioritized focus areas. The majority of the R&D investments are made in software development and the use of AI. While there are several upgrades of the instrument portfolio to meet customer needs. One example of a software upgrade is the AI-powered VCD and cell counting on the UP.SIGHT, demonstrating that AI is more than large language models and chat prompts. In this case, AI is used for image-based pattern recognition to detect and segment cells quickly and precisely, even under challenging conditions. And thanks to the new software update in combination with other features, the UP.SIGHT offers a solution that is ten times faster to results compared to sequential viable cell counting. Compared to the industry standard, savings are estimated to 200,000 to 300,000 Swedish kronor per mid-sized cell line development lab. Multiple launches are planned for this year, and these include both software instruments and consumables. We have already launched a few products in Q1, and some more are around the corner, which were pre-launched at the major Lab Automation Congress SLAS in February this year. The G.STATION GEN 2 automates the next generation sequencing library prep workflow, enabling the scalable, cost-efficient production of consistent sequencing-ready libraries for genomics and drug discovery applications. The G.PURE GEN 2 automates DNA purification, delivering rapid, reproducible plastic-tip-free sample cleanup for seamless next generation library prep workflows. And these are just two examples of technology and solutions delivering customer value, which are the results of our efforts within R&D. As presented earlier in this call, we have already integrated assistive AI into our platforms, bringing natural language workflow creation and troubleshooting in Green Button Go, making automation accessible to every scientist in our R&D roadmap for Green Button Go. We're also developing next-generation systems like Crescendo to scale up experiments while keeping humans in the loop. Oversight and data integrity. End to end. So by emphasizing reliability, data integrity, and compliance, we ensure the coming surge of AI driven experiments can run at scale without compromising quality or uptime. Here you can see our strategy 2.0 on a page. Here you can see our strategy BICO 2.0 on a page. Our five strategic focus areas to drive our top line and profitable growth are enabling end-to-end lab automation and scientific workflow solutions, coupled with further development of integrated data, AI, and software solutions, and ensuring regulatory compliance readiness to enable increased sales to pharma. We also want to expand strategic partnerships such as the one with Sartorius and Becton Dickinson, as well as increasing the recurring revenue in 2026. We have and we will continue to execute our strategy with focus on commercial excellence and R&D pipeline that delivers clear customer value and financial discipline for profitable growth. And with our cash position, we can accelerate commercial as well as R&D initiatives and also more seriously, engage in dialogues for bolt-on acquisitions, strengthening our portfolio further. The new capital puts us in a position to support further growth and capture a market recovery. We have also increased our innovation efforts, including software solutions and the use of AI. As I just presented. And above all, we remain committed to supporting our customers' research. I strongly believe in BICO AB's updated vision, which is to enable life science labs to accelerate the discoveries that change lives by providing innovative instruments, software, services, and consumables into one continuous operating system. We create labs where data flows seamlessly. Every experiment advances the next, and breakthroughs move with efficacy from idea to impact. Together, we enable our customers to deliver what matters most: the discoveries that advance human health. This was our final slide before the Q&A. I will now hand over to the Earnings Call host for further instructions.

Operator
19:29 - 19:49

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Ulrich Trattner from DNB Carnegie. Please go ahead.

Ulrich Trattner
19:51 - 20:27

Thank you very much. And good morning. And a few questions on my end. 11% organic growth is obviously strong. And you talk about or highlight strong desktop instrument sales. Can you just sort of highlight what the development has been here through the quarter and changes you're seeing in the dynamics of the market? And I guess you're still seeing delayed purchasing cycles for larger projects. And if you can highlight which products or subsidiaries that are going particularly strong, that would be helpful.

Maria Forss
20:29 - 20:56

As you mentioned, desktop instruments are mainly growing in the quarter. And while larger projects still take longer time to complete in terms of business cycles. So it's our German based companies that are driving the growth when it comes to the desktop instrument sales mainly.

Ulrich Trattner
20:59 - 21:31

Okay, great. And I know that you like to segment it into academic or R&D-focused companies, but is there any specific direction for the subsidiaries, i.e. Is it early research? Is it sort of genomics or diagnostics? What is the general industry trend that is helping you towards the double-digit organic growth?

Maria Forss
21:33 - 22:06

There are still some effects of a muted US academia market, where our companies that are exposed to US academia have had it tougher. At the same time, though, for instance, in Next Generation Sequencing, we can see that there is strong sales growth. And also in customers that have OEM business, we start to see that the business is starting to brighten up a bit.

Ulrich Trattner
22:09 - 22:28

Okay. That's great. That's kind of what I've been seeing as well is trying to get everything in line, and just on the sort of restructuring savings, how much should come through in 2026 versus 2027? I'm not sure you might have addressed it, but I missed it.

Maria Forss
22:30 - 22:31

Can you please repeat that again?

Ulrich Trattner
22:33 - 22:42

How much restructuring savings should come through in 2026 versus, I guess, fully realized in 2027?

Ewa Linsäter
22:43 - 22:54

I think you can start seeing some savings, maybe in the last quarter of 2026, but the main parts will not fall in until 2027.

Ulrich Trattner
22:56 - 23:21

Okay. Great. And last question on my end, before getting back into the Q&A, obviously, seasonally, the smallest quarter on your end, have you sort of deciphered any type of quarterly sales level where you can reach positive adjusted EBITDA on a sustainable basis, or is this fluctuating?

Maria Forss
23:26 - 23:44

It's a good question. I think given that we have done so much transformation of the business, and we have one foot on the gas pedal and one on the brake. I think it's too early to say where that level ultimately lies. So we'll have to come back to you on that one.

Ulrich Trattner
23:46 - 24:20

Sure. Yeah. That's fair enough. Well, thank you very much for your questions. Last question. Sorry, squeezing one additional, and it's obviously a very strong cash flow here in Q1. Is there any spillover effect from late deliveries in Q4, or anything? I know some changes here in working capital helping the cash flow for Q1, but it looks fairly strong. So, any type of one-offs that we should not extrapolate?

Ewa Linsäter
24:23 - 24:48

I don't think there were any delays in the deliveries. What we can see is that we had a really strong Q4, and also some larger entities might pay on the wrong side of the year-end. That is a small effect that you can see, but otherwise it's more that we had a strong Q4 and sales were not as strong in Q1. So that's the main reason.

Ulrich Trattner
24:50 - 24:55

Okay. Great. Thanks for taking my questions and I'll get back into the queue.

Maria Forss
24:56 - 24:56

Thank you.

Operator
25:00 - 25:04

The next question comes from Ludvig Lundgren from Nordea. Please go ahead.

Ludvig Lundgren
25:06 - 25:32

Yes. Hi. And thank you for taking my questions. Starting off with a bit of a follow-up to Ulrich's question there. You highlight that you were somewhat affected by the geopolitical uncertainty during the quarter. So maybe if you can just elaborate a bit on how the quarter developed. And also if this implies that customers might be a bit more hesitant with instrument orders here in the second quarter.

Maria Forss
25:32 - 26:30

Happy to do so. As you saw in my CEO comment, the year started really, really strong in January. And then in February, we got both new tariff discussions, as well as some uncertainty in the Middle East region. And that halted some, and was clearly seen in February to have affected business decisions. As always, the end of the quarter is always better. So we saw things coming back in March again, which then all in all yielded a quarter with strong organic growth of 11%. So some muted academia in the US still. But as I said to Ulrich's question before, we still saw some good growth in other parts of the business, both when it comes to OEM as well as in Next Generation Sequencing.

Ludvig Lundgren
26:33 - 26:40

Okay. Thanks. Very clear. And if you can elaborate a bit on your exposure to the Middle East, do you have any significant sales there?

Maria Forss
26:41 - 26:58

No we don't. It's more that prices of transport and the general uncertainty is, of course, affecting our business as anyone else operating in a global world, but not anything directly.

Ludvig Lundgren
27:01 - 27:23

Okay. Fair enough. And then a final one from my side, just on lab automation and Biosero, which started off a bit slower here, it seems in Q1. So I just wonder what to expect for Q2 and the rest of the year. Is this current activity level a good indicator for what Biosero will deliver in the next few quarters?

Maria Forss
27:24 - 28:03

Yeah. Thank you for that question. As we have been very open about the past quarters, we are investing heavily to make sure that we can close legacy projects, freeing up capacity, and all the different initiatives with different target measures will both strengthen our execution and enhance our scalability and also reinforce our competitiveness moving forward. So, as we never guide forward, I cannot comment on Q2 or future quarters, but we're doing everything in our power to make sure that we can scale that business.

Ludvig Lundgren
28:05 - 28:08

Okay. Thanks. Very clear. I'll jump back into the queue.

Maria Forss
28:09 - 28:10

Thank you. Ludwig.

Operator
28:12 - 28:16

The next question comes from Philip Einerson from Redeye. Please go ahead.

Philip Einerson
28:18 - 28:46

Okay. Hello, everybody. So the presentation was focusing a lot on AI, and I wanted to follow up with a few questions on that. So you sort of emphasize building a data backbone for AI-driven lab automation. Is it possible to quantify the percentage of your installed base currently connected and generating usable data to train AI models.

Maria Forss
28:49 - 29:48

Every single instrument that is used by a customer is generating data that can be used. And in our development that we have now that we're doing in Crescendo, for instance, we're utilizing years of data from different installations to feed our algorithms. But overall, all instruments used by customers are generating data, and instruments are roughly 65% of our sales this quarter. But overall, you should see it as a continuous operating lab flow where data from the dry lab feeds into the wet lab where we are present, and then data flows back to the dry lab again. So it's a continuous loop where several different instruments and players are involved in that total workflow.

Philip Einerson
29:50 - 30:11

Okay. Got it. And maybe then if you could elaborate a little bit on how, sort of the monetization opportunities of the AI and the data you're generating, maybe you could give us some pointers here. Are we talking like subscriptions or usage-based pricing, or what would you expect?

Maria Forss
30:14 - 30:33

I think that's difficult to quantify; overall, as I said in the presentation, AI is an opportunity for us, but putting a number on how much it would generate in terms of sales connected to our instruments. Overall, that's super, super difficult to say.

Philip Einerson
30:43 - 30:50

Okay. Sorry. I had a hard time hearing what you said. It seems there was a connection issue; could you please repeat that?

Maria Forss
30:51 - 31:10

Okay, so when it comes to AI and monetizing it, that is difficult to do. Overall, AI is an opportunity for us rather than a threat. And we put our tech stack together to ensure that whatever AI model our customers are using could be used together with our different solutions.

Philip Einerson
31:12 - 31:14

Okay. Okay. Thank you. That's all for me.

Operator
31:18 - 31:24

There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Maria Forss
31:26 - 31:36

Thank you for all the questions received, and thank you for your continued interest and support in BICO AB (publ) together with Ewa. I wish you all a great Wednesday. Thank you and goodbye.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…